Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 19/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29043870 | 1.00 | USP1 (0.42) | USP1PDE2A | |
| SCHEMBL30462007 | 0.93 | USP1 (0.44) | USP1PDE2A | |
| SCHEMBL29043928 | 0.93 | USP1 (0.44) | USP1PDE2A | |
| SCHEMBL25978533 | 0.90 | USP1 (0.50) | USP1 | |
| SCHEMBL30461986 | 0.86 | USP1 (0.39) | USP1 | |
| SCHEMBL29043885 | 0.86 | USP1 (0.39) | USP1 | |
| SCHEMBL27086980 | 0.85 | USP1 (0.45) | USP1 | |
| SCHEMBL30135385 | 0.85 | USP1 (0.45) | USP1 | |
| SCHEMBL30461997 | 0.85 | PDE2A (0.43) | USP1PDE2A | |
| SCHEMBL25976056 | 0.85 | USP1 (0.43) | USP1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4516779-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025007777-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-118660872-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-116496252-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | USP1 1/4885PDE2A 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.